1,113
Participants
Start Date
May 26, 2023
Primary Completion Date
December 6, 2023
Study Completion Date
May 7, 2024
RSVPreF3 OA investigational vaccine
One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
PCV20
One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
GSK Investigational Site, Antwerp
GSK Investigational Site, Mechelen
GSK Investigational Site, Namur
GSK Investigational Site, Barcelona
GSK Investigational Site, Ghent
GSK Investigational Site, Wetteren
GSK Investigational Site, Kluisbergen
GSK Investigational Site, North Charleston
GSK Investigational Site, DeLand
GSK Investigational Site, Orlando
GSK Investigational Site, Jupiter
GSK Investigational Site, Clearwater
GSK Investigational Site, Largo
GSK Investigational Site, Guntersville
GSK Investigational Site, Cincinnati
GSK Investigational Site, Valencia
GSK Investigational Site, Troy
GSK Investigational Site, West Des Moines
GSK Investigational Site, St Louis
GSK Investigational Site, New Orleans
GSK Investigational Site, Plano
GSK Investigational Site, Frisco
GSK Investigational Site, Mesquite
GSK Investigational Site, Dallas
GSK Investigational Site, Phoenix
GSK Investigational Site, Huntington Beach
GSK Investigational Site, Modesto
GSK Investigational Site, Hamden
GSK Investigational Site, Krakow
GSK Investigational Site, Lodz
GSK Investigational Site, Lublin
GSK Investigational Site, Pu?awy
GSK Investigational Site, Staszów
GSK Investigational Site, Warsaw
GSK Investigational Site, Warsaw
GSK Investigational Site, Warsaw
GSK Investigational Site, Wroclaw
GSK Investigational Site, Barcelona
Lead Sponsor
GlaxoSmithKline
INDUSTRY